Arbor Metals to Assess Strategic Claims Adjacent to Its Jarnet Lithium Project in Quebec, Canada 28-07-2023, 13:00

Io Therapeutics, Inc., presented today results from studies of IRX4204, the company’s phase II clinical development stage, highly selective RXR nuclear receptor agonist compound, supporting its potential use for treatment of amyotrophic lateral sclerosis 16-07-2024, 20:26

VG-Shipping acquired a stake in Rederi Ab Nathalie, 8-03-2023, 14:41